nach oben

vorheriger Artikel Natural killer cell based immunotherapy for era...

nächster Artikel Evolving strategies to overcome endocrine resis...

Tipp

The role of biomarkers in the choice of therapy in breast cancer

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2012

Autoren:: MD Brigitte Mlineritsch, MD Sigrun Ressler, MD Prof. Richard Greil

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. CrossRefPubMed

Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28. CrossRefPubMed

Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4. CrossRefPubMed

Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46. CrossRefPubMed

Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36. CrossRefPubMed

Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92. CrossRefPubMed

Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102. CrossRefPubMed

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72. CrossRefPubMed

Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153. CrossRefPubMed

10.

Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918. CrossRefPubMed

11.

Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7. CrossRef

12.

Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15.

13.

Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72. CrossRef

14.

Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62. CrossRef

15.

Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69. PubMed

16.

Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7. CrossRef

17.

Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6. CrossRefPubMed

18.

Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608. CrossRefPubMed

19.

Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823. CrossRefPubMed

20.

Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95. CrossRefPubMed

21.

Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988. CrossRefPubMed

22.

Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52. CrossRefPubMed

23.

Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45. CrossRefPubMed

24.

Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62. CrossRefPubMed

25.

Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74. CrossRefPubMed

26.

Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011.

27.

Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. CrossRefPubMed

28.

Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34. CrossRefPubMed

29.

Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157.

Titel: The role of biomarkers in the choice of therapy in breast cancer
Autoren:: MD Brigitte Mlineritsch
MD Sigrun Ressler
MD Prof. Richard Greil
Publikationsdatum: 01.06.2012
DOI: https://doi.org/10.1007/s12254-012-0027-y
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

Lung cancer screening: current evidence and recommendations

Treatment outcome in AML: a single-centre experience in an unselected patient cohort

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Advanced breast cancer: new imaging techniques for detection of metastases

Highlights in the adjuvant treatment of colon cancer from annual meetings 2011